Real‐time cell cycle imaging during melanoma growth, invasion, and drug response
暂无分享,去创建一个
N. Haass | W. Weninger | K. A. Beaumont | D. Hill | A. Anfosso | Paulus Mrass | Marcia A. Munoz | I. Kinjyo | Kimberley A. Beaumont
[1] U. Schumacher,et al. Melanoma never says die , 2014, Experimental dermatology.
[2] P. Gimotty,et al. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines , 2014, Oncogene.
[3] Nikolas K. Haass,et al. Modeling Melanoma In Vitro and In Vivo , 2013, Healthcare.
[4] S. Pavey,et al. DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma , 2013, Pigment cell & melanoma research.
[5] A. Weeraratna,et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. , 2013, Cancer discovery.
[6] R. Dummer,et al. Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. , 2013, The Journal of investigative dermatology.
[7] L. Ng,et al. A quantitative approach to histopathological dissection of elastin‐related disorders using multiphoton microscopy , 2013, The British journal of dermatology.
[8] N. Haass,et al. Melanoma's connections to the tumour microenvironment. , 2013, Pathology.
[9] R. Abraham,et al. Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies , 2012, Pigment cell & melanoma research.
[10] Junji Fukuda,et al. An oxygen-permeable spheroid culture system for the prevention of central hypoxia and necrosis of spheroids. , 2012, Biomaterials.
[11] L. Chin,et al. Melanoma: from mutations to medicine. , 2012, Genes & development.
[12] L. Ng,et al. Intravital multiphoton imaging of immune responses in the mouse ear skin , 2012, Nature Protocols.
[13] P. Hersey,et al. Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737 , 2011, Clinical Cancer Research.
[14] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Dummer,et al. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status , 2011, Pigment cell & melanoma research.
[16] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[17] M. Herlyn,et al. PLX4032, a potent inhibitor of the B‐Raf V600E oncogene, selectively inhibits V600E‐positive melanomas , 2010, Pigment cell & melanoma research.
[18] K. Hoek,et al. Cancer stem cells versus phenotype‐switching in melanoma , 2010, Pigment cell & melanoma research.
[19] M. Shackleton. Moving targets that drive cancer progression. , 2010, The New England journal of medicine.
[20] Alexander Roesch,et al. A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.
[21] A. Santiago-Walker,et al. Melanocytes: From Morphology to Application , 2009, Skin Pharmacology and Physiology.
[22] M. Herlyn,et al. Melanoma and the tumor microenvironment , 2008, Current oncology reports.
[23] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[24] Atsushi Miyawaki,et al. Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression , 2008, Cell.
[25] R. Dummer,et al. In vivo switching of human melanoma cells between proliferative and invasive states. , 2008, Cancer research.
[26] M. Herlyn,et al. The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel , 2008, Clinical Cancer Research.
[27] M. Herlyn,et al. In vitro three-dimensional tumor microenvironment models for anticancer drug discovery , 2008, Expert opinion on drug discovery.
[28] J. Aguirre-Ghiso,et al. Models, mechanisms and clinical evidence for cancer dormancy , 2007, Nature Reviews Cancer.
[29] J. McNamara. Cancer Stem Cells , 2007, Methods in Molecular Biology.
[30] K. Flaherty,et al. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels , 2007, British Journal of Cancer.
[31] Jane Goodall,et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. , 2006, Genes & development.
[32] Lai Guan Ng,et al. Random migration precedes stable target cell interactions of tumor-infiltrating T cells , 2006, The Journal of experimental medicine.
[33] D. Schadendorf,et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.
[34] I. Tannock,et al. Drug penetration in solid tumours , 2006, Nature Reviews Cancer.
[35] Keith T Flaherty,et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.
[36] R. Scolyer,et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma , 2005, Journal of Clinical Pathology.
[37] Eric Brown,et al. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. , 2005, The American journal of pathology.
[38] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[39] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[40] R. Durand. Use of Hoechst 33342 for cell selection from multicell systems. , 1982, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[41] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[42] M. Herlyn,et al. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. , 2012, Advances in pharmacology.
[43] P. Friedl,et al. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. , 2012, Trends in molecular medicine.
[44] K. Flaherty,et al. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. , 2007, Cancer research.
[45] K. Groebe,et al. Distributions of oxygen, nutrient, and metabolic waste concentrations in multicellular spheroids and their dependence on spheroid parameters , 2004, European Biophysics Journal.